Effect of serum of end stage renal disease patients undergoing different types of blood purification on ABCA1 expression in macrophages

2013 ◽  
Vol 32 (11) ◽  
pp. 1217-1222
Author(s):  
Jian-min WANG ◽  
Hua GAN ◽  
Hang WANG
2018 ◽  
Vol 315 (4) ◽  
pp. F890-F902 ◽  
Author(s):  
James G. Atherton ◽  
David S. Hains ◽  
John Bissler ◽  
Bradford D. Pendley ◽  
Ernő Lindner

Current dialysis-dosing calculations provide an incomplete assessment of blood purification. They exclude clearances of protein-bound uremic toxins (PB-UTs), such as polyamines, p-cresol sulfate, and indoxyl sulfate, relying solely on the clearance of urea as a surrogate for all molecules accumulating in patients with end-stage renal disease (ESRD). PB-UTs clear differently in dialysis but also during normal renal function. The kidney clears PB toxins via the process of secretion, whereas it clears urea through filtration. Herein, we review the clearance, accumulation, and toxicity of various UTs. We also suggest possible methods for their monitoring toward the ultimate goal of a more comprehensive dialysis prescription. A more inclusive dialysis prescription would retain the kidney-filtration surrogate, urea, and consider at least one PB toxin as a surrogate for UTs cleared through cellular secretion. A more comprehensive assessment of UTs that includes both secretion and filtration is expected to result in a better understanding of ESRD toxicity and consequently, to reduce ESRD mortality.


Sign in / Sign up

Export Citation Format

Share Document